Furthermore, preclinical studies have shown promise in CaMKII-targeted therapies for the treatment of cognitive dysfunction in schizophrenia: CaMKII activation by ST101 in an NVH lesion model of schizophrenia enhanced cognition (Yabuki et al., 2019). The gene discussed is CAMK2G; the disease is schizophrenia.